Molecular Advances in Oncologic Photodynamic Therapy
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: closed (20 April 2025) | Viewed by 14621
Special Issue Editor
2. Jiaxing Key Laboratory for Photonanomedicine and Experimental Therapeutics, Department of Pharmaceutics, College of Medicine, Jiaxing University, Jiaxing 314041, China
Interests: molecular oncology; photodynamic therapy; chemotherapy; photosensitization; surgery; gastroenterology; liver diseases; nanotechnology; medicinal chemistry; biochemistry; immunology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Oncological photodynamic therapy is an expanding field that has produced clinical treatment modalities for cancer, especially in cases of superficially located tumors. For non-superficial tumors, PDT still suffers from several challenges that have hampered the widespread implementation of PDT in patients with deeper rooted malignancies. In this Special Issue, we would like to focus on studies that address the following challenges so as to ultimately bring PDT of non-superficial tumors closer to clinical application. First, intravenous injection of free photosensitizer molecules leads to their systemic clearance and accumulation in the skin, which reduces the extent of tumor photosensitization and results in skin phototoxicity. To this end, photonanomedicines have been developed that comprise photosensitizers packaged into targeted photosensitizer delivery systems. Studies are, therefore, welcome that describe novel photosensitizers and nanoparticulate photosensitizer delivery systems and demonstrate their rudimentary in vitro proof-of-concepts (intracellular delivery and localization, dark toxicity; PDT efficacy) and in vivo utility (toxicology, pharmacokinetics, disposition and biodistribution, and pharmacodynamics). Models and methodological approaches used to assess these outcome parameters are also eligible on the condition that these are novel, state-of-the-art, or provide unprecedented insights. Second, therapeutic efficacy relies on the degree that post-PDT survival signaling is suppressed and cell death is induced. Molecular biology studies on these phenomena and pharmacological strategies or interventions to inhibit survival pathways or induce tumor cell death will also be published. Third, the post-PDT immune response is critical in long-term tumor control and abscopal effects. Papers that shed new light on anti-tumor immune mechanisms and studies that deal with post-PDT immunomodulation to favor therapeutic outcomes (e.g., checkpoint inhibitors; vaccines) will be considered. Finally, molecular biology and bioinformatics have evidenced that PDT modifies certain pathways that are associated with a poor clinical prognosis, such as phenotypic features related to tumor cell stemness (e.g., PDT-mediated downregulation of certain CD antigens, such as CD44 and CD133). Manuscripts that address any topic in this niche will also be added to the Special Issue.
Prof. Dr. Michal Heger
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- oncology
- photodynamic therapy
- photosensitizer
- targeted drug delivery system
- photonanomedicines
- phototoxicity
- photo cytotoxicity
- dark toxicity
- superficial tumors
- intracellular delivery and localization
- anti-tumor immunity
- bioinformatics analysis
- therapy-induced tumor cell death
- stemness of cancer cells
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
